Alizyme Plc, a UK speciality pharmaceutical company, has announced the departure of its finance director, David Campbell, and its non-executive director, Richard Forrest. Both departures coincide with the publication of the company’s 2008 first-half-year results and a statement by the auditors, Deloitte & Touche, about the company’s ability to continue as a going concern.
